Skip to main content

Publications

Found 66 results
Author Title [ Year(Desc)]
Filters: Keyword is Pregnancy and Author is Laura A Magee  [Clear All Filters]
2008
Magee LA, Helewa M, Rey E. Diagnosis, evaluation, and management of the hypertensive disorders of pregnancy. J Obstet Gynaecol Can. 2008;30(3 Suppl):S1-S2.  (1.73 MB)
2011
Kozic J, Benton S, Hutcheon J, Payne BA, Magee LA, von Dadelszen P. Abnormal liver function tests as predictors of adverse maternal outcomes in women with preeclampsia. J Obstet Gynaecol Can. 2011;33(10):995-1004.  (280.12 KB)
Tsigas E, Magee LA. Advocacy organisations as partners in pre-eclampsia progress: patient involvement improves outcomes. Best Pract Res Clin Obstet Gynaecol. 2011;25(4):523-36.  (438.09 KB)
Payne BA, Magee LA, von Dadelszen P. Assessment, surveillance and prognosis in pre-eclampsia. Best Pract Res Clin Obstet Gynaecol. 2011;25(4):449-62.  (178.71 KB)
Magee LA, von Dadelszen P, Allen V, Ansermino JM, Audibert F, Barrett J, et al.. The Canadian Perinatal Network: a national network focused on threatened preterm birth at 22 to 28 weeks' gestation. J Obstet Gynaecol Can. 2011;33(2):111-120.  (322.85 KB)
Millman A, Payne BA, Qu Z, M Douglas J, Hutcheon J, Lee T, et al.. Oxygen saturation as a predictor of adverse maternal outcomes in women with preeclampsia. J Obstet Gynaecol Can. 2011;33(7):705-714.  (383.37 KB)
Payne BA, Magee LA, Côté A-M, Hutcheon J, Li J, Kyle PM, et al.. PIERS proteinuria: relationship with adverse maternal and perinatal outcome. J Obstet Gynaecol Can. 2011;33(6):588-597.  (292.91 KB)
Payne BA, Magee LA, Côté A-M, Hutcheon J, Li J, Kyle PM, et al.. PIERS proteinuria: relationship with adverse maternal and perinatal outcome. J Obstet Gynaecol Can. 2011;33(6):588-597.  (292.91 KB)
von Dadelszen P, Payne BA, Li J, Ansermino JM, F Pipkin B, Côté A-M, et al.. Prediction of adverse maternal outcomes in pre-eclampsia: development and validation of the fullPIERS model. Lancet. 2011;377(9761):219-27.  (201.46 KB)
Laskin S, Payne BA, Hutcheon J, Qu Z, M Douglas J, Ford J, et al.. The role of platelet counts in the assessment of inpatient women with preeclampsia. J Obstet Gynaecol Can. 2011;33(9):900-8.  (370.8 KB)
Magee LA, Lowe S, M Douglas J, Kathirgamanathan A. Therapeutics and anaesthesia. Best Pract Res Clin Obstet Gynaecol. 2011;25(4):477-90.  (187.9 KB)
Yen T-W, Payne BA, Qu Z, Hutcheon J, Lee T, Magee LA, et al.. Using clinical symptoms to predict adverse maternal and perinatal outcomes in women with preeclampsia: data from the PIERS (Pre-eclampsia Integrated Estimate of RiSk) study. J Obstet Gynaecol Can. 2011;33(8):803-809.  (269.78 KB)
2014
Magee LA, von Dadelszen P, Asztalos E, Ross S, Rey E. 34 weeks of gestation-lost in translation. J Obstet Gynaecol Can. 2014;36(6):480-481.  (706.24 KB)
Nensi A, De Silva D, von Dadelszen P, Sawchuck D, Synnes A, Crane J, et al.. Effect of magnesium sulphate on fetal heart rate parameters: a systematic review. J Obstet Gynaecol Can. 2014;36(12):1055-1064.  (1.57 MB)
Gillon T, Pels A, von Dadelszen P, MacDonell K, Magee LA. Hypertensive disorders of pregnancy: a systematic review of international clinical practice guidelines. PLoS One. 2014;9(12):e113715.  (359.44 KB)
Gordon R, Magee LA, Payne BA, Firoz T, Sawchuck D, Tu D, et al.. Magnesium sulphate for the management of preeclampsia and eclampsia in low and middle income countries: a systematic review of tested dosing regimens. J Obstet Gynaecol Can. 2014;36(2):154-163.  (1.42 MB)
Firoz T, Magee LA, MacDonell K, Payne BA, Gordon R, Vidler M, et al.. Oral antihypertensive therapy for severe hypertension in pregnancy and postpartum: a systematic review. BJOG. 2014;121(10):1210-8; discussion 1220.  (158.15 KB)
Akkermans J, Payne BA, von Dadelszen P, Groen H, de Vries J, Magee LA, et al.. Predicting complications in pre-eclampsia: external validation of the fullPIERS model using the PETRA trial dataset. Eur J Obstet Gynecol Reprod Biol. 2014;179:58-62.  (317.15 KB)
von Dadelszen P, Magee LA. Pre-eclampsia: an update. Curr Hypertens Rep. 2014;16(8):454.  (486.35 KB)
Payne BA, Hutcheon J, Ansermino JM, Hall D, Bhutta ZA, Bhutta ZA, et al.. A risk prediction model for the assessment and triage of women with hypertensive disorders of pregnancy in low-resourced settings: the miniPIERS (Pre-eclampsia Integrated Estimate of RiSk) multi-country prospective cohort study. PLoS Med. 2014;11(1):e1001589.  (353.97 KB)
Livingston J, Payne BA, Brown M, Roberts J, Côté A-M, Magee LA, et al.. Uric Acid as a predictor of adverse maternal and perinatal outcomes in women hospitalized with preeclampsia. J Obstet Gynaecol Can. 2014;36(10):870-877.  (1021.64 KB)
2015
Payne BA, Hutcheon J, Dunsmuir D, Cloete G, Dumont G, Hall D, et al.. Assessing the incremental value of blood oxygen saturation (SpO(2)) in the miniPIERS (Pre-eclampsia Integrated Estimate of RiSk) Risk Prediction Model. J Obstet Gynaecol Can. 2015;37(1):16-24.  (1.11 MB)
Payne BA, Groen H, Ukah V, Ansermino JM, Bhutta ZA, Grobman W, et al.. Development and internal validation of a multivariable model to predict perinatal death in pregnancy hypertension. Pregnancy Hypertens. 2015;5(4):315-21.  (505.41 KB)
Khowaja A, Mitton C, Bryan S, Magee LA, Bhutta ZA, von Dadelszen P. Economic evaluation of Community Level Interventions for Pre-eclampsia (CLIP) in South Asian and African countries: a study protocol. Implement Sci. 2015;10:76.  (1.88 MB)
Magee LA, Pels A, Helewa M, Rey E, von Dadelszen P. The hypertensive disorders of pregnancy (29.3). Best Pract Res Clin Obstet Gynaecol. 2015;29(5):643-57.  (227.04 KB)
Magee LA, Namouz-Haddad S, Cao V, Koren G, von Dadelszen P. Labetalol for hypertension in pregnancy. Expert Opin Drug Saf. 2015;14(3):453-61.  (463.16 KB)
Magee LA, Singer J, von Dadelszen P. Less-tight versus tight control of hypertension in pregnancy. N Engl J Med. 2015;372(24):2367-8.  (515.75 KB)
De Silva D, Sawchuck D, von Dadelszen P, Basso M, Synnes A, Liston R, et al.. Magnesium Sulphate for Eclampsia and Fetal Neuroprotection: A Comparative Analysis of Protocols Across Canadian Tertiary Perinatal Centres. J Obstet Gynaecol Can. 2015;37(11):975-87.  (362.1 KB)
Teela K, De Silva D, Chapman K, Synnes A, Sawchuck D, Basso M, et al.. Magnesium sulphate for fetal neuroprotection: benefits and challenges of a systematic knowledge translation project in Canada. BMC Pregnancy Childbirth. 2015;15:347.  (549.75 KB)
von Dadelszen P, Magee LA, Payne BA, Dunsmuir D, Drebit S, Dumont G, et al.. Moving beyond silos: How do we provide distributed personalized medicine to pregnant women everywhere at scale? Insights from PRE-EMPT. Int J Gynaecol Obstet. 2015;131 Suppl 1:S10-5.  (662.6 KB)
2016
Magee LA, von Dadelszen P, Singer J, Lee T, Rey E, Ross S, et al.. Can adverse maternal and perinatal outcomes be predicted when blood pressure becomes elevated? Secondary analyses from the CHIPS (Control of Hypertension In Pregnancy Study) randomized controlled trial. Acta Obstet Gynecol Scand. 2016;95(7):763-76.  (803.67 KB)
Magee LA, von Dadelszen P, Singer J, Lee T, Rey E, Ross S, et al.. The CHIPS Randomized Controlled Trial (Control of Hypertension in Pregnancy Study): Is Severe Hypertension Just an Elevated Blood Pressure?. Hypertension. 2016;68(5):1153-1159.  (476.19 KB)
Firoz T, Vidler M, Makanga P, Boene H, Chiaú R, Sevene E, et al.. Community perspectives on the determinants of maternal health in rural southern Mozambique: a qualitative study. Reprod Health. 2016;13(Suppl 2):112.  (1019.85 KB)
Magee LA, von Dadelszen P, Singer J, Lee T, Rey E, Ross S, et al.. Control of Hypertension In Pregnancy Study randomised controlled trial-are the results dependent on the choice of labetalol or methyldopa?. BJOG. 2016;123(7):1135-41.  (144.71 KB)
Ahmed R, Gafni A, Hutton E, Hu Z, Pullenayegum E, von Dadelszen P, et al.. The Cost Implications of Less Tight Versus Tight Control of Hypertension in Pregnancy (CHIPS Trial). Hypertension. 2016;68(4):1049-55.  (470.91 KB)
Magee LA, von Dadelszen P, Singer J, Lee T, Rey E, Ross S, et al.. Do labetalol and methyldopa have different effects on pregnancy outcome? Analysis of data from the Control of Hypertension In Pregnancy Study (CHIPS) trial. BJOG. 2016;123(7):1143-51.  (153.93 KB)
Robertson J, Lisonkova S, Lee T, De Silva D, von Dadelszen P, Synnes A, et al.. Fetal, Infant and Maternal Outcomes among Women with Prolapsed Membranes Admitted before 29 Weeks Gestation. PLoS One. 2016;11(12):e0168285.  (862.28 KB)
Benton S, McCowan L, Heazell AEP, Grynspan D, Hutcheon J, Senger C, et al.. Placental growth factor as a marker of fetal growth restriction caused by placental dysfunction. Placenta. 2016;42:1-8.  (475.29 KB)
Mol B, Roberts C, Thangaratinam S, Magee LA, de Groot C, Hofmeyr J. Pre-eclampsia. Lancet. 2016;387(10022):999-1011.  (128.83 KB)
von Dadelszen P, Magee LA. Preventing deaths due to the hypertensive disorders of pregnancy. Best Pract Res Clin Obstet Gynaecol. 2016;36:83-102.  (389.82 KB)
Duffy J, Hooft Jvan 't, Gale C, Brown M, Grobman W, Fitzpatrick R, et al.. A protocol for developing, disseminating, and implementing a core outcome set for pre-eclampsia. Pregnancy Hypertens. 2016;6(4):274-278.  (336.66 KB)
Ryan H, Sharma S, Magee LA, Ansermino JM, MacDonell K, Payne BA, et al.. The Usefulness of the APACHE II Score in Obstetric Critical Care: A Structured Review. J Obstet Gynaecol Can. 2016;38(10):909-918.  (304.95 KB)
Vidler M, Magee LA, von Dadelszen P, Rey E, Ross S, Asztalos E, et al.. Women's views and postpartum follow-up in the CHIPS Trial (Control of Hypertension in Pregnancy Study). Eur J Obstet Gynecol Reprod Biol. 2016;206:105-113.  (412.73 KB)

Pages